Medical Supplies Stocks on Investors' Radar -- Insulet, Glaukos, West Pharmaceutical Services, and TransEnterix

Wednesday, November 15, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 15, 2017 /PRNewswire/ --

If you want a Stock Review on PODD, GKOS, WST, or TRXC then come over

to and sign up for your free customized report. On Tuesday, November 14, 2017, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions in
red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,737.87, down 0.29%; the Dow Jones Industrial Average edged 0.13% lower, to finish at 23,409.47; and the S&P 500 closed at 2,578.87, down 0.23%. This Wednesday morning, looks at the performance of these four Medical Instruments & Supplies stocks: Insulet Corp. (NASDAQ: PODD), Glaukos Corp. (NYSE: GKOS), West Pharmaceutical Services Inc. (NYSE: WST), and TransEnterix Inc. (NYSE AMER: TRXC). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:


On Tuesday, shares in Billerica, Massachusetts headquartered Insulet Corp. recorded a trading volume of 506,448 shares. The stock ended the session 1.23% lower at $67.42. The Company's shares have gained 11.46% in the last month, 22.60% over the previous three months, 94.35% in the past twelve months, and 78.93% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 12.21% and 35.32%, respectively. Moreover, shares of Insulet, which develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally, have a Relative Strength Index (RSI) of 61.84.

On November 03rd, 2017, research firm Canaccord Genuity upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $50 a share to $65 a share. Visit us today and download your complete report on PODD for free at:


San Clemente, California headquartered Glaukos Corp.'s stock closed the day 4.50% lower at $28.65 with a total trading volume of 696,218 shares. The stock is trading below its 50-day moving average by 16.25%. Additionally, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 31.09. The complimentary research report on GKOS can be accessed at:

West Pharmaceutical Services 

Shares in Exton, Pennsylvania headquartered West Pharmaceutical Services Inc. recorded a trading volume of 282,207 shares. The stock ended yesterday's trading session 0.77% lower at $100.85. The Company's shares have advanced 17.28% over the previous three months, 30.60% in the past twelve months, and 18.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.50% and 11.59%, respectively. Furthermore, shares of the Company, which manufactures and sells packaging components and delivery systems for injectable drugs and healthcare products in the US, Germany, France, other European countries, and internationally, have an RSI of 60.32.

On October 17th, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Buy' to 'Neutral'. Register for free on and download the research report on WST at:


Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished Tuesday's session 15.67% lower at $2.69 with a total trading volume of 11.95 million shares, which was above their three months average volume of 8.45 million shares. The Company's shares have advanced 292.82% over the previous three months, 65.03% in the past twelve months, and 106.92% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 31.85% and 129.00%, respectively. Additionally, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 51.00.

On October 30th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $3.75 a share to $4 a share. Get free access to your research report on TRXC at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store